Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Bone marrow mesenchymal stem cells (BMSCs) are core stem cells and their differentiation orientation directly manipulates the ongoing of osteoporosis (OP). MicroRNAs (miRNAs) are momentously characterized molecular in BMSCs. However, the leading pattern and trait of miRNAs in OP remain vague and mysterious. Full-scale research of BMSCs-existed miRNA expression between normal conditions and patients experiencing OP is the only way for us to pinpoint the effect of miRNA, making us rationally and effectively utilize miRNA. Objective This review chiefly lies in exploring, selecting, verifying, and confirming the biomarker of miRNAs by dissecting miRNA patterns, which offer diagnosis reference, monitor value, customized feature therapy by developing related preparation, and emerging prognosis indicators. Methods We gathered miRNA-seq datasets from human BMSCs to detect the expression pattern of miRNA. Herein, we searched and distinguished microRNA expression levels of BMSCs, sifted the distinctively existing microRNAs, sought the preferentially expressed microRNAs, had knowledge of the target points of related microRNA biomarkers, and boosted our awareness of the role of miRNAs and the development of pharmaceutical preparation aimed at it. Results These miRNAs manifested aberrant expression variation between matched control and OP cases, they mainly draw upon the Wnt/β-catenin, MAPK, and Notch pathways to perform signal delivery, mediating the osteogenesis, adipogenesis, the balance of these two kinds of differentiated conversion, the proliferation, migration, apoptosis, stemness, and senescence of BMSCs, and biological ongoing of chondrocytes and osteoclasts. In addition, the treatment based on miRNAs of in vitro trials in combination with animal models defined the application of miRNA-linked therapy. Conclusion This paper accorded proof of miRNAs as screening tools, confirmation guidance, treatment means, and prediction indicators of OP, paved the emerging road for clinical practice, and pushed the development of personalized remedies that break through regular remedies.
Background Bone marrow mesenchymal stem cells (BMSCs) are core stem cells and their differentiation orientation directly manipulates the ongoing of osteoporosis (OP). MicroRNAs (miRNAs) are momentously characterized molecular in BMSCs. However, the leading pattern and trait of miRNAs in OP remain vague and mysterious. Full-scale research of BMSCs-existed miRNA expression between normal conditions and patients experiencing OP is the only way for us to pinpoint the effect of miRNA, making us rationally and effectively utilize miRNA. Objective This review chiefly lies in exploring, selecting, verifying, and confirming the biomarker of miRNAs by dissecting miRNA patterns, which offer diagnosis reference, monitor value, customized feature therapy by developing related preparation, and emerging prognosis indicators. Methods We gathered miRNA-seq datasets from human BMSCs to detect the expression pattern of miRNA. Herein, we searched and distinguished microRNA expression levels of BMSCs, sifted the distinctively existing microRNAs, sought the preferentially expressed microRNAs, had knowledge of the target points of related microRNA biomarkers, and boosted our awareness of the role of miRNAs and the development of pharmaceutical preparation aimed at it. Results These miRNAs manifested aberrant expression variation between matched control and OP cases, they mainly draw upon the Wnt/β-catenin, MAPK, and Notch pathways to perform signal delivery, mediating the osteogenesis, adipogenesis, the balance of these two kinds of differentiated conversion, the proliferation, migration, apoptosis, stemness, and senescence of BMSCs, and biological ongoing of chondrocytes and osteoclasts. In addition, the treatment based on miRNAs of in vitro trials in combination with animal models defined the application of miRNA-linked therapy. Conclusion This paper accorded proof of miRNAs as screening tools, confirmation guidance, treatment means, and prediction indicators of OP, paved the emerging road for clinical practice, and pushed the development of personalized remedies that break through regular remedies.
Dietary phytic acid/phytate/myo-inositol hexaphosphate (IP6), a phosphate reservoir in plants, was viewed as antinutrient, caused by an influence on the bioavailability of minerals through its chelating activity. However, there is a growing body of evidence indicating that IP6 has beneficial (e.g., antiinflammatory, antibacterial, and anticancer) effects on multiple biological processes. Also, IP6 and its metabolites are known to exist in mammalian cells, including human cells, and the role of IP6 as a functional molecule is attracting attention. IP6 can bind to the growth sites of hydroxy-apatite (HA) and calcium oxalate crystals to prevent their growth and hence inhibit pathological calcification. SNF472, hexasodium IP6, is currently being evaluated in clinical studies as a treatment for vascular calcification and calciphylaxis. However, since HA crystal growth within bone matrix is an essential process in bone formation, it is possible that IP6 intake may inhibit physiological mineralization and bone formation, although currently more published studies suggest that IP6 may contribute to bone health rather than inhibit bone formation. Given that IP6 and its metabolites are thought to have diverse activities and many health benefits, it remains important to consider the range of effects of IP6 on bone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.